2020
Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology
Yumeen S, Mirza FN, Lewis JM, Girardi M. Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology. Journal Of Investigative Dermatology 2020, 140: 2319-2325.e1. PMID: 33222758, DOI: 10.1016/j.jid.2020.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDermatologyDrug Screening Assays, AntitumorDrug SynergismHigh-Throughput Screening AssaysHumansMiceResearch DesignSkin NeoplasmsConceptsCombination regimensCutaneous malignanciesMalignant cellsRelevant mouse modelPotential synergistic combinationsAdvanced cutaneous malignanciesClinical trial designChou-Talalay methodCancer cell linesClinical outcomesTherapy regimensDefinitive cureTargeted therapyTumor cell heterogeneityDrug combinationsMouse modelTrial designPreclinical developmentDrug resistanceRegimensCombination indexSynergistic activityOff-target effectsCritical pathwaysCell lines
2017
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
Cyrenne BM, Lewis JM, Weed JG, Carlson KR, Mirza FN, Foss FM, Girardi M. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood 2017, 130: 2073-2083. PMID: 28972015, PMCID: PMC5680613, DOI: 10.1182/blood-2017-06-792150.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaB-cell lymphoma 2Advanced cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsHDAC inhibitionT-cell lymphoma patientsNovel BCL2 inhibitorPeripheral blood involvementAvailable systemic therapiesWorse clinical outcomesTreatment of patientsNon-Hodgkin lymphomaT-cell lymphomaCTCL cell linesPotential therapeutic targetHistone deacetylase inhibitionQuality of lifeHistone deacetylase inhibitorsBlood involvementSystemic therapyClinical outcomesTumor burdenLymphoma patientsCombination therapyBCL2 inhibitors